Episode
Zachary Roberts: Building a Viable Off-the-Shelf CAR T
- Podcast
- Behind the Breakthroughs
- Published
- Jan 28, 2026
- Duration seconds
- 3374
- Processing state
not_requested- Canonical source
- https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/zachary-roberts-building-a-viable-off-the-shelf-car-t
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-breakthroughs-7055075/episodes/zachary-roberts-building-a-viable-off-the-shelf-car-t/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-breakthroughs-7055075/zachary-roberts-building-a-viable-off-the-shelf-car-t.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Cancer immunotherapy evolved through decades of research, with watershed moments like checkpoint inhibitor approvals and the first CAR T trial results reshaping expectations. For Zachary Roberts, MD, PhD, witnessing CAR T-induced remissions as a Mass General resident convinced him of the field’s future and drew him from academia into drug development. Now as CMO and EVP of R&D at Allogene Therapeutics, he’s focused on the next inflection point: transforming CAR T into scalable, off-the-shelf therapies that could broaden access and extend impact beyond cancer to autoimmune disease. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.